chief medical officer

Miguel is a physician and researcher with more than 35 years researching cancer and the development of novel anticancer agents. As a researcher, he has more than 100 international publications in the field of Substance P / NK-1R in cancer with over 4,000 citations and he is international referee of over 110 peer reviews journals. As clinician, he has been involved in several compassionate, off-label prescribing of substance P antagonists, establishing the validity of this novel approach to cancer therapy. He holds a Ph.D in Medicine from University of Seville.